RCM
TEVA icon

Royal Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Royal Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-115,000
Closed -$6.03M – 17
2014
Q2 		$6.03M Hold
115,000
– – 5.17% 9
2014
Q1 		$6.08M Sell
115,000
-107,500
-48% -$4.97M 4.59% 10
2013
Q4 		$8.92M Buy
+222,500
New +$8.76M 6.05% 8

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Royal Capital Management's TEVA Position: Q3 2014 in Review

Royal Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2014, closing a stake of 115,000 shares — an estimated $6.03M sold.

Royal Capital Management first reported a position in TEVA in Q4 2013 and held it in 3 quarters. The position peaked at $8.92M in Q4 2013. 773 funds tracked by Wall St. Rank hold TEVA as of Q3 2014.

  • Royal Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Royal Capital Management sold 115,000 Teva Pharmaceuticals shares in Q3 2014, an estimated $6.03M.
  • Royal Capital Management first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • Royal Capital Management's Teva Pharmaceuticals position peaked at $8.92M in Q4 2013.
  • 773 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2014.

Based on Royal Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.